Document Detail

Primary malignant giant-cell tumor of bone has high survival rate.
MedLine Citation:
PMID:  19902306     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Malignant giant-cell tumors (MGCT) comprise 2-9% of all giant-cell tumors (GCTs). The limited existing studies fail to distinguish primary, secondary, or postradiation cancers, making it difficult to design rational treatment strategies. This study compared malignant to benign GCTs and defined the clinical outcome of the patients in a large series of case-matched patients from a single institution. METHODS: Clinical, radiological, and outcome features were compared between 26 malignant and 244 benign GCTs treated in our institution. Five postradiation cancers were excluded. We also performed a 1:2 case-matched comparison of patients with malignant and benign disease. RESULTS: Distal femur (P = 0.019), proximal tibia (P = 0.032), and distal tibia (P = 0.049) had a higher frequency of MGCT. Campanacci stage 1 tumors had a low probability of malignancy (P = 0.017). MGCT were less likely to have aneurysmal bone cyst changes. The 5-year recurrence-free status probability was 80% for malignant and 91% for benign cases in matched groups. The difference in the recurrence rate between benign and malignant groups was not statistically significant (P = 0.24). Functional impairment and limited activity were greater in MGCT patients than in benign GCT patients, whether treated by resection/amputation or curettage/cryosurgery. CONCLUSIONS: We found that malignant and benign GCT have similar epidemiology and that recurrence was higher in MGCT (20 v 9%). Local recurrence for MGCT was not statistically different for excision versus intralesional therapy, but there was little statistical power. Finally, the 16% mortality for patients with MGCT suggests low-grade malignancy.
Stepan V Domovitov; John H Healey
Related Documents :
25147796 - Tattoo-associated skin reaction: the importance of an early diagnosis and proper treatm...
25230556 - Testicular embryonal cell carcinoma presenting as haemoptysis and skin nodules.
21299686 - Diagnostic accuracy of t-cell interferon-gamma release assays in tuberculous pleurisy: ...
20815946 - Prostatic atrophy. clinicopathological significance.
999306 - Lichen planus pemphigoides. immunofluorescence findings.
18313966 - Buschke-ollendorff syndrome.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2009-11-10
Journal Detail:
Title:  Annals of surgical oncology     Volume:  17     ISSN:  1534-4681     ISO Abbreviation:  Ann. Surg. Oncol.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-12     Completed Date:  2010-05-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9420840     Medline TA:  Ann Surg Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  694-701     Citation Subset:  IM    
Orthopaedic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Neoplasms / mortality*,  pathology,  surgery
Case-Control Studies
Giant Cell Tumor of Bone / mortality*,  pathology,  surgery
Neoplasm Recurrence, Local / mortality*,  pathology,  surgery
Retrospective Studies
Survival Rate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Spatial Displacement of Release Point can Enhance Activity of an Attractant Pheromone Synergist of a...
Next Document:  Functional recovery following an end to side neurorrhaphy of the accessory nerve to the suprascapula...